RDHL RedHill Biopharma Ltd. Stock Quote

RDHL [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | Israel

Index	-	P/E	-	EPS (ttm)	-2.30	Insider Own	-	Shs Outstand	46.68M	Perf Week	-45.60%
Market Cap	246.93M	Forward P/E	-	EPS next Y	-0.33	Insider Trans	-	Shs Float	34.99M	Perf Month	-30.25%
Income	-95.00M	PEG	-	EPS next Q	-0.16	Inst Own	18.40%	Short Float	5.28%	Perf Quarter	-30.75%
Sales	84.50M	P/S	2.92	EPS this Y	-46.80%	Inst Trans	-26.59%	Short Ratio	2.46	Perf Half Y	-35.13%
Book/sh	0.63	P/B	7.65	EPS next Y	50.00%	ROA	-49.10%	Target Price	-	Perf Year	-55.49%
Cash/sh	1.08	P/C	4.47	EPS next 5Y	-	ROE	-303.30%	52W Range	4.65 - 11.52	Perf YTD	-40.35%
Dividend	-	P/FCF	-	EPS past 5Y	-1.90%	ROI	-63.20%	52W High	-58.16%	Beta	1.49
Dividend %	-	Quick Ratio	1.10	Sales past 5Y	635.00%	Gross Margin	50.50%	52W Low	3.66%	ATR	0.74
Employees	182	Current Ratio	1.20	Sales Q/Q	2.90%	Oper. Margin	-91.40%	RSI (14)	29.13	Volatility	9.85% 8.60%
Optionable	Yes	Debt/Eq	2.97	EPS Q/Q	-39.00%	Profit Margin	-	Rel Volume	1.27	Prev Close	4.86
Shortable	Yes	LT Debt/Eq	2.91	Earnings	Aug 26 BMO	Payout	-	Avg Volume	753.10K	Price	4.82
Recom	1.70	SMA20	-39.11%	SMA50	-33.11%	SMA200	-36.99%	Volume	954,751	Change	-0.82%

Aug-31-21

Initiated

Cantor Fitzgerald

Overweight

$22

May-18-21

Initiated

H.C. Wainwright

Buy

$23

Sep-11-20

Initiated

BTIG Research

Buy

Jul-12-19

Upgrade

WBB Securities

Buy → Strong Buy

Mar-12-19

Upgrade

WBB Securities

Speculative Buy → Buy

Jan-26-18

Initiated

Nomura

Buy

$18

Oct-06-17

Initiated

Seaport Global Securities

Buy

$19

Oct-04-17

Reiterated

H.C. Wainwright

Buy

$33 → $36

Feb-24-17

Reiterated

FBR & Co.

Outperform

$36 → $25

Jul-27-16

Reiterated

FBR Capital

Outperform

$33 → $36

Sep-29-15

Initiated

Nomura

Buy

Jul-29-15

Reiterated

ROTH Capital

Buy

$30 → $31

Jun-17-15

Reiterated

H.C. Wainwright

Buy

$23 → $32

Jun-15-15

Reiterated

ROTH Capital

Buy

$27.50 → $30

Sep-15-21 11:40AM	RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study Zacks
Sep-14-21 12:02PM	Why RedHill Biopharma Stock Is Getting Crushed Today Motley Fool -32.66%
08:15AM	RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients PR Newswire
Sep-13-21 09:10AM	RedHill Biopharma To Test Its Oral Antiviral In COVID-19 Patients In South Africa Benzinga -8.66%
07:02AM	RHB-107 P2/3 COVID-19 Study South Africa Approval ACCESSWIRE
07:00AM	RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval PR Newswire
Sep-08-21 10:29AM	RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis Zacks -7.64%
Sep-07-21 07:56AM	RedHill Unveils New Movantik Data For Opioid-Induced Constipation Benzinga
07:02AM	RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis ACCESSWIRE
06:02AM	RedHill Biopharma Ltd Announces New Movantik Analyses at PAINWeek ACCESSWIRE
06:00AM	RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021 PR Newswire
Sep-02-21 10:35AM	RedHill to Present at HCW & Cantor Conferences ACCESSWIRE
10:00AM	RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences PR Newswire
Sep-01-21 10:44AM	Biotech Stock Roundup: REGN Gives Study Update, INCY Wins Drug Approval & More Zacks
Aug-31-21 04:11PM	Why RedHill Biopharma Stock Jumped on Tuesday Motley Fool +17.58%
Aug-26-21 08:44AM	RedHill Biopharma's Oral COVID-19 Candidate Shows Preclinical Action Against Delta Variant Benzinga
07:56AM	RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights PR Newswire
07:50AM	RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant PR Newswire
07:30AM	RedHill Reports Second Quarter 2021 Results ACCESSWIRE
07:00AM	RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights CNW Group
06:30AM	RedHill Biopharma Ltd Announces RedHill's Opaganib Strong Delta Variant Inhibition ACCESSWIRE
06:00AM	RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant PR Newswire
06:00AM	RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant CNW Group
Aug-23-21 07:05AM	RedHill Announces Two New U.S. Patents ACCESSWIRE
07:00AM	RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's CNW Group
Aug-19-21 07:00AM	RedHill Biopharma to Host Second Quarter 2021 Financial Results and Operational Highlights Webcast on August 26, 2021 PR Newswire
Jul-22-21 09:45AM	RedHill Settles Movantik(R) Apotex Patent Litigation ACCESSWIRE
09:19AM	RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex PR Newswire
Jul-20-21 08:00AM	RedHill Extends Talicia Commercial Coverage ACCESSWIRE +10.86%
07:00AM	RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx PR Newswire
Jul-19-21 10:15AM	RedHill Biopharma Announces Last Patient Out ACCESSWIRE
07:21AM	RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib PR Newswire
07:00AM	RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib PR Newswire
07:00AM	RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib CNW Group
Jul-13-21 11:00AM	RedHill Biopharma's Movantik® Added as Unrestricted Preferred Brand To A Major National Commercial Formulary Serving over 30 Million Americans PR Newswire
Jun-28-21 07:00AM	RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study PR Newswire
Jun-21-21 07:30AM	QuestEx Receives Multi-Year Permit for Drilling on the Sofia Property and Commences Exploration Program CNW Group
07:00AM	RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19 PR Newswire
07:00AM	RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19 CNW Group
Jun-18-21 02:53PM	Is RDHL Stock A Buy Here? Insider Monkey
Jun-15-21 03:04PM	Top Pharmaceutical Stocks for Q3 2021 Investopedia
Jun-09-21 07:00AM	RedHill Biopharma to Present at the BIO Digital International Convention PR Newswire
Jun-07-21 07:00AM	RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study PR Newswire
May-27-21 07:15PM	35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021 ACCESSWIRE
07:05AM	Strength Seen in Redhill Biopharma Ltd. (RDHL): Can Its 5.4% Jump Turn into More Strength? Zacks
07:00AM	RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights PR Newswire
06:45AM	RedHill Biopharma Ltd. to Host Earnings Call ACCESSWIRE
May-26-21 11:06AM	3 Strong Buy Stocks Under $10 With Triple-Digit Upside Potential TipRanks +5.38%
07:12AM	RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 PR Newswire
07:00AM	RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 PR Newswire
May-25-21 08:00AM	RedHill's Novel Late-Stage Pills Hold Promise Against COVID-19 and its Variants Benzinga
May-24-21 07:00AM	RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021 PR Newswire
May-21-21 12:15PM	RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021 PR Newswire
May-20-21 07:00AM	RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021 PR Newswire
Apr-11-21 06:15AM	Could These 2 Exciting COVID Stocks be 10-Baggers? Motley Fool
Apr-09-21 07:00AM	RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue PR Newswire +8.94%
Mar-25-21 09:15AM	RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN Pharmaceuticals PR Newswire
Mar-22-21 07:00AM	RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland PR Newswire
Mar-18-21 08:18AM	Recap: Redhill Biopharma Q4 Earnings Benzinga -6.19%
Mar-11-21 07:00AM	RedHill Biopharma to Host Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Webcast on March 18, 2021 PR Newswire +5.80%
Mar-05-21 07:00AM	RedHill to Present at Upcoming Conferences in March PR Newswire
Mar-04-21 12:10PM	RedHill Biopharma Announces Closing of $35 Million Bought Deal Offering of American Depositary Shares PR Newswire
Mar-02-21 09:06AM	ObvioHealth and RedHill Biopharma Launch First in Kind Remote COVID-19 Therapy Trial Incorporating Highest Level of At-home Patient Monitoring to Date PR Newswire -15.49%
08:23AM	RedHill Biopharma Increases Previously Announced Bought Deal to $35 Million of American Depositary Shares PR Newswire
Mar-01-21 04:53PM	RedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary Shares PR Newswire
Feb-23-21 08:07AM	RedHill Biopharma Expands Opaganib Global COVID-19 Study To US Benzinga -13.29%
07:33AM	RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S. PR Newswire
07:13AM	RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S. PR Newswire
07:03AM	RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S. PR Newswire
Feb-18-21 01:00PM	RedHill Biopharma, Cosmo Pharma In Manufacturing Pact for Movantik, RHB-204 Benzinga
07:00AM	RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204 PR Newswire
Feb-17-21 07:00AM	RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107 PR Newswire
Feb-11-21 06:55AM	4 Top COVID Stocks to Buy in February Motley Fool
Feb-09-21 07:00AM	RedHill Biopharma to Present at SVB Leerink Global Healthcare and BIO CEO & Investor Conferences PR Newswire
Jan-29-21 07:45AM	The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO Benzinga
07:26AM	RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib PR Newswire
07:00AM	RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib PR Newswire
Jan-28-21 09:03AM	RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals PR Newswire
08:02AM	RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals PR Newswire
07:27AM	RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals PR Newswire
Jan-26-21 06:20AM	These 2 Coronavirus Stocks Could Soar in the First Half of 2021 Motley Fool +5.69%
Jan-14-21 02:13PM	RedHill Biopharma Announces Closing of $25 Million Bought Deal Offering PR Newswire
Jan-12-21 12:56PM	Why RedHill Biopharma Stock Is Tanking Today Motley Fool -13.66%
08:51AM	RedHill Biopharma Increases Previously Announced Bought Deal to $25 Million PR Newswire
Jan-11-21 04:35PM	RedHill Biopharma Announces $10 Million Bought Deal Offering PR Newswire
07:00AM	RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D PR Newswire
07:00AM	RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D CNW Group
Jan-08-21 02:11PM	Government of Canada awards contract for inspection, repair and overhaul of service boats CNW Group
Jan-07-21 09:28AM	RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation Zacks +5.01%
Jan-06-21 07:00AM	RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease PR Newswire
Jan-04-21 09:41AM	RedHill (RDHL) COVID-19 Drug Shows Promise in Mid-Stage Study Zacks
Dec-31-20 09:38AM	RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib PR Newswire -5.61%
09:30AM	RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib PR Newswire
Dec-28-20 11:28AM	Is the Options Market Predicting a Spike in RedHill Biopharma (RDHL) Stock? Zacks
Dec-22-20 07:00AM	RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue PR Newswire
Dec-15-20 11:42AM	RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model PR Newswire
09:30AM	RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model CNW Group
Dec-14-20 08:00AM	RedHill Biopharma Added to NASDAQ Biotechnology Index PR Newswire +5.20%
Dec-07-20 07:00AM	RedHill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to Over 40 Million Additional Americans PR Newswire
Nov-29-20 09:45PM	RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19 PR Newswire

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience